ANGKA FIB-4 DAN HIGHLY ACTIVE ANTI RETROVIRAL THERAPY DI ANTARA PASIEN PENGIDAP INFEKSI HIV

Liliana A, Noormartany Noormartany, Sugianli AK

Abstract


Liver disease in patients with HIV infection can be caused by hepatotropical virus co infection or as a side effect of antiretroviral
therapy. The cause of HAART effects on liver fibrosis among patients with HIV infection is not yet known. The monitoring of the incidence
of liver fibrosis can be done with non-invasive markers, such as FIB 4 score. FIB-4 score is calculated by the formula: Age x AST/total
platelet x √ALT. This is carried out to know the comparison of the FIB-4 score in HIV patients before and after first-line HAART therapy,
with or without HCV coinfection. This study was a comparative analysis of retrospective data of patients at the Outpatient Teratai Clinic,
Dr. Hasan Sadikin Hospital, from 2003 through 2013. The research subjects consisted of 64 patients with HIV infection who received
first-line HAART therapy for more than 12 months. Statistical analysis was performed by Wilcoxon test for two paired samples. The
median scores of FIB-4 from HIV infection patients with or without HCV co infection before and after the administration of first-line
HAART therapy were 0.854 and 0.906 (p=0.837). The HCV co infected patients had median scores of FIB-4 before and after treatment at
0.854 and 0.899 (p=0.204). Those without HCV co infection had median scores of FIB-4 before and after treatment at 2.726 and 0.912
(p=0.013).Treatment with first-line HAART did not lead to a change in the FIB-4 score. Those who were co infected with HCV showed no
differences in the FIB-4 scores before and after treatment with first-line HAART.


Keywords


FIB-4, HAART, liver fibrosis, HIV, HCV

Full Text:

PDF


DOI: http://dx.doi.org/10.24293/ijcpml.v20i2.1071

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.